Inovio Pharmaceuticals, Inc. · NASDAQ:INO
Inovio Pharmaceuticals — Q1 2025 Earnings Presentation
21 slides from Inovio Pharmaceuticals's earnings presentation, May 13, 2025
Slide 1: First Quarter 2025 Financial Results
First Quarter 2025 Financial Results May 2025
Slide 2: Agenda
Agenda Introduction Jennie Willson, Director, Communications CEO Perspective & Corporate Progress Jacqueline Shea, PhD, President & Chief Executive Officer INO-3107 Update Michael Sumner, MBBS, MBA, Chief Medical Officer Steve Egge, MBA, Chief Commercial Officer Financial Results Peter Kies, Chief F
Slide 3: Forward-Looking Statements
Forward-Looking Statements This presentation includes statements that are, or may be deemed, “forward-looking statements,” within the meaning of Section 27A of the Securities Act of 1933, as amended. All statements, other than statements of historical facts, included in this presentation regarding o
Slide 4: Recent Progress on 2025 Strategic and Priorities
Recent Submit BLA for INO-3107 Progress • On track to begin rolling submission of BLA in mid-2025 on 2025 - Initiated device design verification (DV) testing required for IND update Strategic and BLA submission - Aim to complete submission in the 2H25, receive acceptance from FDA Priorities by EOY;
Slide 5: Lead Candidate: INO-3107 for Recurrent Respiratory Papillomatosis (RRP)
Lead Candidate: INO-3107 for Recurrent Respiratory Papillomatosis (RRP) Potentially transformational therapy under accelerated approval pathway
Slide 6: Continued Progress Toward BLA Goal
INO-3107 DELIVERING THERAPEUTIC INNOVATION TO PATIENTS Continued Progress Toward BLA Goal Regulatory & Manufactured new arrays and initiated DV testing Device Progress • On track to begin rolling submission of BLA in mid-2025 Confirmatory Targeting 20+ sites at major US medical centers Trial Prepara
Slide 7: Targeted Outreach at Key Scientific Conferences
INO-3107 Targeted Outreach at Key Scientific Conferences MARCH /APRIL MAY • Eurogin – MARCH 16 • European Laryngological Society Annual Congress – MAY 9 • National HPV Conference – APRIL 15 - First ever HPV conference to be held in US • American Society of Gene and Cell - Highlighted impact of HPV a
Slide 8: Key Takeaway: Significant Reduction in Surgeries for Majority of Patients
INO-3107 KEY TAKEAWAY: Significant Reduction in Surgeries for Majority of Patients, Continued Improvement Over Time RRP-001 PHASE 1/2 OPEN-LABEL STUDY RRP-002 DURABILITY EXTENSION / FOLLOW-UP • Statistically significant reduction in surgeries • Reduction in surgeries continued to improve after for R
Slide 9: Next Steps
INO-3107 Next Steps Regulatory • Complete DV testing first half of 2025 • Begin rolling submission of BLA mid-2025 with goal of completing the submission in 2H25 and receiving FDA acceptance for filing of submission by end of year; plan to request priority review • Submit revised IND for confirmator
Slide 10: RRP Represents a Significant Market Opportunity
RRP Represents a Significant Market Opportunity Disease-modifying therapeutic option 14,000 patients in the U.S., 1.8 per No regulatory-approved 100,000 new cases annually; therapeutic currently available similar estimates in Europe HPV vaccination unlikely to Surgical standard of care has have sign
Slide 11: Recent Market Research Supports Preferred Product Profile
INO-3107 Recent Market Research Supports Preferred Product Profile HCP PERSPECTIVE The complete response rate of 50% is good... Improving response over time but a 50-100% reduction in surgeries in ~8 out if 10 Efficacy • Patients that achieved a 50% to 100% reduction in patients, that’s the most com
Slide 12: Next-Gen DNA Medicines Platform
Next-Gen DNA Medicines Platform • Initial interim clinical data announced March 2025 • Additional data to be presented at ASGCT in May
Slide 13: The Next Generation of DNA Medicine
DMAbTM DNA ENCODED MONOCLONAL ANTIBODIES The Next Generation of DNA Medicine MYOCYTE DMAb technology enables in vivo production of monoclonal antibodies (mAbs) • DNA is administered via CELLECTRA device to enable local expression of the genes coding for the antibodies in the deltoid muscle. • DMAbs
Slide 14: Ongoing Phase Trial: Key Takeaways From Interim Data
DMAbTM Ongoing Phase 1 Trial: Key Takeaways From Interim Data • Long-lasting in vivo antibody production: DMAb levels remained stable for 72 weeks in DURABLE AND CONSISTENT DMAb EXPRESSION all participants reaching that timepoint 1024 4 x 0.5 mg Serum Concentration, ng/mL 512 2 x 0.5 mg • No anti-dr
Slide 15: Potential to Address Challenges of Conventional mAbs
DMAbTM Potential to Address Challenges of Conventional mAbs Challenges with mAbs1 INOVIO’s DMAb technology • Stability: susceptible to a variety of chemically- • Rapid manufacturing, low cost of production, and and temperature-induced structural changes temperature-stable storage and distribution •
Slide 16: 1Q25 Financial Update
1Q25 Financial Update
Slide 17: Making Progress on Strategic Goals While Reducing Costs
Making Progress on Strategic Goals While Reducing Costs Three Months Ended Three Months Ended March 31, 2025 March 31, 2024 % (unaudited) (unaudited) CHANGE Operating expenses $25.1 $31.5 (20%) Net loss ($19.7) ($30.5) (35%) Net loss per share ($0.51) ($1.31) (61%) • $68.4M in cash, cash equivalents
Slide 18: Q&A
Q&A
Slide 19: Upcoming Key Catalysts
Upcoming Key Catalysts Commercialization Submit BLA for INO-3107 Preparations Progress Pipeline • Request rolling review & begin • Be ready to launch quickly DMAb submitting modules mid-2025 and efficiently if approved • Complete Phase 1 trial - Goal: receive acceptance of • Continue to build on mar
Slide 20: Why each day—and each surgery—matters to RRP patients
Why each day—and each surgery—matters to RRP patients: “ RRP patients will tell you that even one reduction in the number of disruptive, invasive surgeries they face would be life-changing.” Kim McClellan President, RRP Foundation 20
Slide 21: Contact: investor.relations@inovio.com
Contact: investor.relations@inovio.com
Inovio Pharmaceuticals — Q1 2025 Earnings Presentation on 6ix